Literature DB >> 15282394

alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.

J K Stoller1, L S Aboussouan.   

Abstract

The biochemical and clinical efficacy of intravenous augmentation therapy in alpha(1)-antitrypsin deficiency is reviewed, adverse events experienced with this treatment are considered, and its cost effectiveness is discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15282394      PMCID： PMC1747086          DOI： 10.1136/thx.2003.006544

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  21 in total

1.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Authors:  A Dirksen; J H Dijkman; F Madsen; B Stoel; D C Hutchison; C S Ulrik; L T Skovgaard; A Kok-Jensen; A Rudolphus; N Seersholm; H A Vrooman; J H Reiber; N C Hansen; T Heckscher; K Viskum; J Stolk
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

2.  Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.

Authors:  Thomas R Gildea; Kenneth M Shermock; Mendel E Singer; James K Stoller
Journal:  Am J Respir Crit Care Med       Date:  2003-02-05       Impact factor: 21.405

3.  Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.

Authors:  M Wencker; N Banik; R Buhl; R Seidel; N Konietzko
Journal:  Eur Respir J       Date:  1998-02       Impact factor: 16.671

4.  The direct medical costs of alpha(1)-antitrypsin deficiency.

Authors:  C D Mullins; X Huang; S Merchant; J K Stoller
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

5.  Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.

Authors:  M Wencker; B Fuhrmann; N Banik; N Konietzko
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

6.  Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis.

Authors:  S A Alkins; P O'Malley
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

7.  Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.

Authors:  D J Gottlieb; M Luisetti; P J Stone; L Allegra; J M Cantey-Kiser; C Grassi; G L Snider
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

8.  The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.

Authors:  Robert A Stockley; Darren L Bayley; Ipek Unsal; Lee J Dowson
Journal:  Am J Respir Crit Care Med       Date:  2002-06-01       Impact factor: 21.405

9.  Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.

Authors:  J Lieberman
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

10.  Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

Authors:  James K Stoller; Farshid Rouhani; Mark Brantly; Seta Shahin; Raed A Dweik; James M Stocks; Jack Clausen; Edward Campbell; Frank Norton
Journal:  Chest       Date:  2002-07       Impact factor: 9.410
View more
  10 in total

1.  Alpha-1-antitrypsin augmentation treatment: does one size fit all?

Authors:  J Stolk
Journal:  Thorax       Date:  2006-12       Impact factor: 9.139

2.  Adipose tissue-derived mesenchymal stem cell-based liver gene delivery.

Authors:  Hong Li; Bin Zhang; Yuanqing Lu; Marda Jorgensen; Bryon Petersen; Sihong Song
Journal:  J Hepatol       Date:  2010-11-03       Impact factor: 25.083

3.  Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin.

Authors:  Hong Li; Yuanqing Lu; Rafal P Witek; Lung-Ji Chang; Martha Campbell-Thompson; Marda Jorgensen; Bryon Petersen; Sihong Song
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

4.  How are we in Brazil with the treatment of alpha-1 antitrypsin deficiency?

Authors:  Maria Vera Cruz de Oliveira Castellano; Paulo Henrique Feitosa
Journal:  J Bras Pneumol       Date:  2022-04-29       Impact factor: 2.800

5.  New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Authors:  B Gross; M Grebe; M Wencker; J K Stoller; L M Bjursten; S Janciauskiene
Journal:  Dermatology       Date:  2009-02-16       Impact factor: 5.366

6.  Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.

Authors:  Izabela Nita; Camilla Hollander; Ulla Westin; Sabina-Marija Janciauskiene
Journal:  Respir Res       Date:  2005-01-31

7.  Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells.

Authors:  Gregory B Pott; K Scott Beard; Courtney L Bryan; Daniel T Merrick; Leland Shapiro
Journal:  Front Public Health       Date:  2013-06-21

Review 8.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

9.  There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements.

Authors:  James A Stockley; Robert A Stockley; Elizabeth Sapey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-29

Review 10.  Alpha-1-antitrypsin: A possible host protective factor against Covid-19.

Authors:  Mariana Braccialli de Loyola; Thaís Tereza Aguiar Dos Reis; Guilherme Xavier Lyra Malcher de Oliveira; Julys da Fonseca Palmeira; Gustavo A Argañaraz; Enrique R Argañaraz
Journal:  Rev Med Virol       Date:  2020-08-26       Impact factor: 11.043
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.